Goldman Sachs Knock-Out CHKP/ DE000GJ1DKZ0 /
2024-10-07 10:58:56 AM | Chg.+0.15 | Bid12:42:43 PM | Ask12:42:43 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.61EUR | +10.27% | 1.61 Bid Size: 5,000 |
1.68 Ask Size: 5,000 |
Check Point Software... | 176.0137 USD | 2078-12-31 | Call |
GlobeNewswire
09-03
Check Point Software Unveils New MSSP Portal for Partners: Vastly Simplifying Service Delivery and E...
GlobeNewswire
08-30
Carahsoft Sponsors 15th Annual Billington Cybersecurity Summit in Washington, D.C. on September 3-6...
GlobeNewswire
08-28
Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Pro...
GlobeNewswire
08-28
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
08-27
Check Point Software to Acquire Cyberint to Transform Security Operations and Expand Managed Threat ...
GlobeNewswire
08-14
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
08-14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
08-13
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
08-13
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
GlobeNewswire
08-13
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire
08-13
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
08-12
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024...
GlobeNewswire
08-12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
GlobeNewswire
08-12
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
08-08
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-08
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
08-08
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting
GlobeNewswire
08-08
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update